# Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer

> **NCT04190056** · PHASE2 · TERMINATED · sponsor: **University of California, San Francisco** · enrollment: 1 (actual)

## Conditions studied

- Anatomic Stage IV Breast Cancer AJCC v8
- Prognostic Stage IV Breast Cancer AJCC v8

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Tamoxifen
- **DRUG:** Vorinostat

## Key facts

- **NCT ID:** NCT04190056
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-11
- **Primary completion:** 2023-06-15
- **Final completion:** 2023-06-15
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Change in practice patterns
- **Last updated:** 2023-08-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04190056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04190056, "Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04190056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*